secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyteir Therapeutics, Inc. (—)
CIK:        0001662244
Form:       8-K
Filed at:   2023-01-19T23:59:59+00:00
Accession:  0000950170-23-000928
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyteir cuts 70% of staff, focuses CYT-0851 on ovarian cancer, extends cash runway to 2026
--------------------------------------------------------------------------------

- Workforce reduction of ~70%; expects 15 or fewer employees; charges $2.5M-$3M in Q1 2023.
- Strategic focus on CYT-0851 + capecitabine for platinum-resistant ovarian cancer; Phase 2 monotherapy suspended.
- Preliminary combo: 13 patients, 5 ovarian cancer patients showed responses/disease stabilization at 300-400mg doses.
- Cash runway extended into 2026; $147M cash as of Dec 31, 2022 (unaudited).
- CBO Gengos (Feb 3) and CSO Secrist (Apr 1) depart; CEO retention bonus 150% target if stays through Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662244/000095017023000928/0000950170-23-000928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662244/000095017023000928/cyt-20230112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer